Medications
GLP-1 medication comparison: nutritional impact across the class
How the FDA-approved GLP-1 receptor agonists compare on the dimensions that matter for nutrition: appetite suppression, side-effect timing, dose-day rhythm, and body-composition footprint.
The FDA-approved GLP-1 receptor agonists differ on the dimensions that matter for nutrition: how strongly they suppress appetite, how the dose is scheduled, what the side-effect timing pattern is, and how large the resulting weight-loss and body-composition shifts tend to be. This article lays them side by side.
The comparison table
| Medication | Active ingredient | Schedule | Magnitude of appetite suppression | Typical weight-loss range | Body-composition footprint |
|---|---|---|---|---|---|
| Ozempic | Semaglutide | Once weekly SC | Moderate to high | Variable; FDA-approved for T2D | Lean-mass loss component as in any rapid weight loss |
| Wegovy | Semaglutide | Once weekly SC | High at 2.4 mg dose | ~14-15% over 68 weeks (STEP-1) | Approx. 25-40% of total weight loss is lean tissue |
| Mounjaro | Tirzepatide | Once weekly SC | High | Variable; FDA-approved for T2D | Similar to Zepbound in body-comp substudies |
| Zepbound | Tirzepatide | Once weekly SC | Highest among FDA-approved | ~21% at 15 mg over 72 weeks (SURMOUNT-1) | Approx. 25-40% of total weight loss is lean tissue |
| Saxenda | Liraglutide | Once daily SC | Moderate | ~5-8% over 56 weeks | Lean-mass loss component, smaller absolute magnitude |
| Victoza | Liraglutide | Once daily SC | Moderate | Variable; FDA-approved for T2D | Smaller absolute magnitude |
| Trulicity | Dulaglutide | Once weekly SC | Lower-moderate | Smaller; T2D indication | Smaller absolute magnitude |
| Bydureon | Exenatide ER | Once weekly SC | Lower-moderate | Smaller | Smaller absolute magnitude |
| Rybelsus | Semaglutide oral | Once daily oral | Lower than injectable | Variable; T2D indication | Smaller absolute magnitude |
Note that the typical weight-loss ranges are means from clinical trials; individual response varies substantially.
What this means for nutritional planning
Appetite-suppression magnitude
Higher appetite-suppression magnitude (Wegovy, Zepbound at full dose) translates directly to greater pressure on protein adequacy and micronutrient sufficiency under reduced caloric intake. The protein-and-resistance-training framework is most consequential at the higher doses of these medications. At lower doses (or on Saxenda, Victoza, Trulicity, Rybelsus) the framework still applies but the practical pressure is smaller.
Dose schedule rhythm
Weekly-injection medications produce a recognizable “dose day” pattern in many patients: appetite is most suppressed in the 24-48 hours after injection and gradually returns over the week. Daily-injection (liraglutide) and daily-oral (Rybelsus) medications produce more even drug exposure and less of a recognizable weekly pattern. The practical implication is that weekly-medication patients can sometimes concentrate protein intake into the higher-appetite days; daily-medication patients address daily protein adequacy as the focus.
Titration steps
Tirzepatide has more titration steps than semaglutide (multiple steps from 2.5 mg to 15 mg, with 4 weeks at each step). The practical implication is that the patient experiences more dose-escalation episodes — and each is a fresh occasion of more pronounced side effects for 1-2 weeks. Nutritional planning that accommodates a periodic 1-2-week reduced-tolerance phase repeats across each escalation.
Side-effect profile
The side-effect profiles across the class are similar: nausea, occasional vomiting, constipation, and (less commonly) diarrhea. The published trial evidence does not strongly differentiate the medications on side-effect rate; individual experience varies.
Body-composition footprint
Body-composition substudies across the trial program (STEP for semaglutide, SURMOUNT for tirzepatide, SCALE for liraglutide) report lean-mass-loss proportions in similar ranges (approximately 25-40% of total weight loss), with substantial variability across studies, doses, and analysis methods. The magnitude of absolute lean-mass loss is larger when the absolute weight loss is larger; this is the underlying reason that the protein-and-resistance-training framework is more consequential on Wegovy and Zepbound than on Saxenda or Trulicity.
Practical takeaways
- The protein-target framework applies across the class but is most consequential at the higher doses of semaglutide and tirzepatide.
- Side-effect-management strategies are broadly similar across the class.
- Hydration and micronutrient considerations apply most strongly when total caloric intake drops most significantly — i.e., on the higher doses of the higher-magnitude medications.
- Schedule choice (daily vs weekly) has implications for the rhythm of side effects and the rhythm of nutritional planning.
- Switching between medications is a clinical decision involving the prescribing clinician, not a casual change.
References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216.
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine. 2015;373(1):11-22.
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021;385(6):503-515.
- Holmstrup ME, Fairman CM, Calanna S, et al. Body composition during pharmacologic weight loss with GLP-1 receptor agonists: implications for protein adequacy and resistance training. Obesity Reviews. 2025;26(4):e13721.
- American Diabetes Association. Standards of Care in Diabetes — 2025: Section 9, Pharmacologic approaches to glycemic treatment. Diabetes Care. 2025;48(Suppl 1):S158-S178.